Mizuho Reiterates $63.00 Price Target for Aerie Pharmaceuticals (NASDAQ:AERI)

Share on StockTwits

Mizuho set a $63.00 target price on Aerie Pharmaceuticals (NASDAQ:AERI) in a research report sent to investors on Friday morning, TipRanks reports. The firm currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Canaccord Genuity set a $56.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, June 11th. JMP Securities dropped their price objective on shares of Aerie Pharmaceuticals from $58.00 to $52.00 and set a market outperform rating on the stock in a report on Thursday, August 8th. ValuEngine upgraded shares of Aerie Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 1st. Needham & Company LLC restated a buy rating and set a $54.00 price objective (down previously from $74.00) on shares of Aerie Pharmaceuticals in a report on Thursday, August 8th. Finally, BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, August 13th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $61.00.

AERI traded up $0.69 during trading on Friday, hitting $23.88. The stock had a trading volume of 616,364 shares, compared to its average volume of 709,182. The firm has a market cap of $1.07 billion, a PE ratio of -5.14 and a beta of 0.41. Aerie Pharmaceuticals has a 12 month low of $20.72 and a 12 month high of $64.45. The company has a current ratio of 2.52, a quick ratio of 3.27 and a debt-to-equity ratio of 0.08. The company has a 50 day simple moving average of $24.25 and a 200-day simple moving average of $36.91.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Wednesday, August 7th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.07. The firm had revenue of $15.84 million for the quarter, compared to the consensus estimate of $14.60 million. Aerie Pharmaceuticals had a negative net margin of 478.81% and a negative return on equity of 89.52%. As a group, sell-side analysts anticipate that Aerie Pharmaceuticals will post -3.48 earnings per share for the current fiscal year.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Management Ii bought 100,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were acquired at an average price of $23.73 per share, with a total value of $2,373,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 8.71% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of AERI. Meeder Asset Management Inc. lifted its position in Aerie Pharmaceuticals by 134.0% during the first quarter. Meeder Asset Management Inc. now owns 1,060 shares of the company’s stock worth $50,000 after buying an additional 607 shares in the last quarter. JGP Global Gestao de Recursos Ltda. lifted its holdings in Aerie Pharmaceuticals by 10.4% in the first quarter. JGP Global Gestao de Recursos Ltda. now owns 8,523 shares of the company’s stock valued at $405,000 after buying an additional 800 shares during the period. Quantamental Technologies LLC acquired a new position in Aerie Pharmaceuticals in the first quarter valued at approximately $41,000. Oppenheimer Asset Management Inc. acquired a new position in Aerie Pharmaceuticals in the first quarter valued at approximately $47,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Aerie Pharmaceuticals by 2,330.0% in the second quarter. Tower Research Capital LLC TRC now owns 1,458 shares of the company’s stock valued at $43,000 after buying an additional 1,398 shares during the period.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Recommended Story: What is total return in investing?

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.